Market Overview
The global mesenchymal stem cells market size reached USD 3.7 Billion in 2024. It is forecasted to grow at a CAGR of 11.17% during 2025-2033 to reach USD 10.0 Billion by 2033. The market growth is driven by the rising prevalence of chronic diseases, advancements in stem cell research, increasing clinical trials, and greater investments in healthcare. Enhanced regulatory support globally also propels MSC-based therapies adoption.
Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033
Mesenchymal Stem Cells Market Key Takeaways
• The global mesenchymal stem cells market size was USD 3.7 Billion in 2024.
• The market is expected to grow at a CAGR of 11.17% during 2025-2033.
• The forecast market value is USD 10.0 Billion by 2033.
• The rising prevalence of chronic diseases, advancements in stem cell technologies, and increased clinical trials are significant growth drivers.
• The market witnesses a shift towards allogeneic MSC therapies due to off-the-shelf availability and scalability.
• North America leads the market, driven by advanced healthcare infrastructure and research funding.
• The application in cardiovascular diseases shows clear dominance due to the critical need for innovative heart treatments.
Sample Request Link:
https://www.imarcgroup.com/mesenchymal-stem-cells-market/requestsample
Market Growth Factors
However, the mesenchymal stem cells market is mainly driven by the increasing incidence of chronic diseases around the world, advancements in stem cell research, and ever-increasing demands for regenerative medicine. Supportive regulatory environments and heavy investments by both governmental and private bodies, along with the rising number of clinical trials and approval of mesenchymal stem cell-based products, strongly fuel the growth of this market. Joint initiatives by biotechnology corporations, research institutes, and healthcare facilities accelerate product development and entry into the market.
Important developments in biotech are improving MSC therapeutic uses and expanding the scope of disease treatment. A significant trend emerging is towards allogeneic MSC therapies. This is mainly due to their ready availability and scalability. Approvals are accelerating in North America and Europe. This helps increase the adoption of MSC therapies. A key trend here is collaboration between academic and biopharmaceutical industries.
Growing investment leads to more innovative and burgeoning advances within the MSC market. For instance, the Indian government showed their commitment to research and development in the fields of stem cell research with the involvement of various institutions such as ICMR, DBT, and DST that allocated funds to over 40 institutions with adequate financial resources committed between 2019 and 2021. This is really helpful for advancements and applications.
Market Segmentation
Product & Services
• Products: This segment includes cells and cell lines, kits, media, reagents, and others. Products hold the largest market share, driven by applications in regenerative medicine and treatment of chronic diseases like cardiovascular and autoimmune disorders where MSCs promote tissue repair and immune modulation.
• Services: Includes various support and development services associated with MSC-based therapies.
Type
• Autologous: MSCs derived from the patient's own cells.
• Allogeneic: Accounts for the largest market share due to ready availability, immediate usability, donor sourcing from multiple patients, and scalability for mass production reducing costs and facilitating clinical use.
Source of Isolation
• Bone Marrow: Leading segment owing to its well-established history, proven efficacy, versatility in differentiation to bone, cartilage, and muscle, and established extraction and cultivation methods.
• Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues: Other sources of MSCs.
Indication
• Bone and Cartilage Repair: Utilization in tissue repair.
• Cardiovascular Disease: Dominates the market due to MSCs' ability to regenerate heart tissue, modulate immune response, and promote angiogenesis crucial for myocardial infarction and heart failure treatment.
• Inflammatory and Immunological Diseases, Liver Diseases, Cancer, GvHD, Others: Additional therapeutic areas.
Application
• Disease Modelling: Largest segment, driven by the need for advanced models in drug development and discovery using MSCs to simulate diseases in vitro and evaluate therapies.
• Drug Development and Discovery: Utilizes MSCs to advance therapeutic research.
• Stem Cell Banking: Preservation of MSCs for future use.
• Tissue Engineering: MSCs used for regenerative therapies.
• Toxicology Studies: Application in safety evaluation of drugs.
Regional Insights
North America leads the mesenchymal stem cells market due to its robust healthcare infrastructure, significant stem cell research investments, and favorable regulatory environment. The region's market dominance is supported by the high prevalence of chronic diseases, like cardiovascular disorders, and government-backed initiatives. For instance, heart disease caused about 695,000 deaths in the US in 2021, costing approximately USD 239.9 billion annually. Government funding and supportive frameworks continue to solidify North America's leadership in MSC market growth.
Recent Developments & News
In 2023, ATCC and USP formed a strategic collaboration to provide solutions and standards for safer and higher-quality biologics, including co-branded reference materials and standards. In 2024, Axol Bioscience launched the axoCells Atrial Cardiomyocyte kit for better modeling of heart arrhythmia and cardiotoxicity. Also in 2024, Lonza Group AG agreed to acquire Genentech’s Vacaville manufacturing facility from Roche for USD 1.2 billion, aiming to enhance biologics manufacturing capacity and expand US presence, with sales CAGR guidance updated to 12–15%.
Key Players
• ATCC
• Axol Bioscience Ltd.
• Cell Applications Inc.
• Celprogen Inc.
• Cyagen Biosciences Inc.
• Lonza Group AG
• Merck KGaA
• PromoCell GmbH
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=8062&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Share this page with your family and friends.